NCT03101696 is a clinical trial in Coronary Artery Stenosis of Unclear Hemodynamic Relevance, sponsored by Heinrich-Heine University, Duesseldorf.

Who is sponsoring NCT03101696?

NCT03101696 is sponsored by Heinrich-Heine University, Duesseldorf.

What condition does NCT03101696 study?

NCT03101696 studies Coronary Artery Stenosis of Unclear Hemodynamic Relevance.

Is NCT03101696 still recruiting?

NCT03101696 is currently completed. Last updated 26 March 2019.

Last reviewed 2019-03-26 · How we verify

NCT03101696

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determination of Coronarphysiological Parameters With the Method of Thermodillution

Completed Last updated 26 March 2019

What this trial tests

trial in Coronary Artery Stenosis of Unclear Hemodynamic Relevance in 50 participants. Completed in 28 February 2019.

Timeline

5 February 2017

Primary endpoint
28 February 2019

28 February 2019

Quick facts

Lead sponsor	Heinrich-Heine University, Duesseldorf
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	5 February 2017
Primary completion	28 February 2019
Estimated completion	28 February 2019
Sites	1 location across Germany

Conditions studied

Coronary Artery Stenosis of Unclear Hemodynamic Relevance — all drugs for Coronary Artery Stenosis of Unclear Hemodynamic Relevance →

Sponsor

Heinrich-Heine University, Duesseldorf

Who can join

18 and older, any sex, with Coronary Artery Stenosis of Unclear Hemodynamic Relevance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The gold standard to induce coronary hyperemia for measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) is adenosine, but it exerts several side effects due to its unspecific action on adenosine receptors. The specific A2a-receptor agonist, regadenoson, has been shown to dilate coronary arteries and enables FFR measurements. The aim of the study was to evaluate whether simultaneous measurement of FFR, CFR and IMR is feasible, safe and effective within regadenoson-induced hyperemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Heinrich-Heine University, Duesseldorf trials

Trials by the same sponsor.

NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
NCT07254663 — GEL & MEDication Dysphagia · recruiting
NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03101696 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
Last refreshed: 26 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03101696.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing